Cancer-Linked Mutations Identified as Potential Drivers of Alzheimer’s

Researchers at Boston Children's Hospital have identified a significant genetic overlap between Alzheimer’s disease and blood cancers. The study reveals that microglia—the brain’s primary immune cells—accumulate mutations in specific genes typically associated with leukemia and lymphoma. Rather than triggering malignancy, these genetic alterations appear to drive the neuroinflammation characteristic of Alzheimer’s, suggesting that the disease may share a common biological foundation with certain blood cancers.

By analyzing brain and blood tissue from hundreds of individuals, the research team discovered that the same cancer-associated mutations present in the brain were also circulating in the patients' blood. This indicates that immune cells originating in the bloodstream may cross the blood-brain barrier, infiltrating the brain and adopting microglia-like functions. Once inside, these mutated cells likely exacerbate the inflammatory response to protein buildup, accelerating the progression of cognitive decline.

This discovery offers a promising new frontier for clinical intervention. Because the medical community has already developed a robust arsenal of therapies to target these specific cancer-driving mutations, researchers believe existing oncology drugs could potentially be repurposed to treat Alzheimer’s. Furthermore, the presence of these mutations in blood samples could pave the way for non-invasive, blood-based diagnostic screenings, offering a more accessible method for early detection of the disease.